The second International Consensus Report of the Precision Medicine in Diabetes Initiative (PMDI) highlights that there are significant differences in the disease. Because of this diversity of diabetes, the risks of secondary diseases and mortality also vary widely. As part of this report, researchers have been working on tailored approaches to the prevention, diagnosis and treatment of diabetes.
More than 200 scientists from 28 countries participated in the report. The DZD experts Prof. Norbert Stefan from the Institute of Diabetes Research and Metabolic Diseases of Helmholtz Munich at the University of Tübingen and Prof. Robert Wagner, Dr. Katsiaryna Prystupa and Dr. Martin Schön from the German Diabetes Center in Düsseldorf have worked particularly on precision diagnostics for type 2 diabetes, which is described in detail in an additional publication in the scientific journal 'Communications Medicine'.
The researchers emphasize the importance of developing personalized treatments for diabetes patients, similar to those used in cancer medicine. These should take into account the diversity of the disease and be implementable in everyday clinical practice. The differentiation into the subtypes of diabetes, which were also identified by DZD researchers, is proving to be very helpful.